Myositis Induced by Isotretinoin: A Case Report and Literature Review

Julián Alejandro Rivillas
Victor Alfonso Santos Andrade
Andrés Alberto Hormaza-Jaramillo

Corresponding Author: Andrés Hormaza-Jaramillo, e-mail: andreshormazaj@hotmail.com

Conflict of interest: None declared

Patient: Male, 45-year-old
Final Diagnosis: Myositis induced by isotretinoin
Symptoms: Muscle pain in the upper limbs with marked functional limitation associated by coluria
Medication: —
Clinical Procedure: —
Specialty: Rheumatology

Objective: Unusual clinical course

Background: Retinoid-induced myositis is a rare condition encountered in clinical practice. Its occurrence implies a diagnostic challenge due to the multiple causes associated with myopathic syndromes. The most common clinical presentation is generalized affection. Focal myositis is even less frequent and easily misdiagnosed as muscular disease of other etiology.

Case Report: We describe a case of 45-year-old male with a history of nephrolithiasis and rosacea diagnosed by dermatology, who was management with isotretinoin 1 mg/kg per day in 2 doses with clinical improvement. Later, he presents muscle pain in the upper limbs with marked functional limitation associated by choloria, without muscular pains in other location; he had no history of using another medication. At his physical examination, vital signs were normal, with edema and pain in the bilateral bicipital region associated with limitation for flexion-extension of shoulders and elbows and high levels of creatine phosphokinase (CPK). He was transferred to the intensive care unit where he received fluid therapy because of the high risk of deterioration of renal function, very high CPK levels, and a history of obstructive uropathy. One year after this hospitalization, the cutaneous symptoms worsened and the patient voluntarily restarted isotretinoin and 5 months later he presented again with the same symptoms of the first episode.

Conclusions: Drug-induced myositis should be taken into consideration in the differential diagnosis of myopathic syndromes. Retinoids have the potential to cause varying degrees of myositis and their rapid identification could prevent major complications.

MeSH Keywords: Creatine Kinase • Dermatomyositis • Myalgia • Retinoids

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/917801
Background

Retinoids are a group of drugs derived from vitamin A widely used for the treatment of different recalcitrant dermatoses and neoplasms. Three generations of retinoids have been described. The first generation are formed by retinoids (retinol, retinal, tretinoin [retinoic acid], isotretinoin and alitretinoin), the second generation are the so-called mono-aromatics (etretinate and their metabolite acitretin) and third generation are the poly-aromatics (adapalene, bexarotene and tazarotene).

The mechanism of action that explains this group of drugs therapeutic effect and profile of adverse events include induction of apoptosis in cells of the neural crest (risk of teratogenicity), epidermal cells (cutaneous pharmacological effects), hepatocytes (release of transaminases and low density lipoproteins), myocytes (myalgias, myositis, and creatine phosphokinase [CPK] increase), as well as other cells [1]. Since the end of the 1980s, the adverse effects of retinoids on the musculoskeletal system have been known, and are clinically evident due to myalgias, cramps, hyperostosis, and arthralgias [2]. In the early 1990s, documented cases of myopathy and myositis associated with this therapy began to be reported [3–5]. We report the case of a patient with multifocal muscle involvement and serum CPK increase associated with the use of isotretinoin indicated by rosacea.

We carried out a search in PubMed, Scopus, and Embase with the terms “myositis”, “retinoid”, and “isotretinoin”, without temporal restriction or by language and those case reports and series of patient cases with retinoid-induced myopathy were selected for review.

Case Report

A 45-year-old male with a history of nephrolithiasis and rosacea diagnosed by dermatology received topical treatment without response. He started management with isotretinoin 1 mg/kg per day in 2 doses with clinical improvement. Three months after the patient began the medication and later an intensive exercise session, he consulted the emergency department because of 3 days of muscle pain in the upper limbs with marked functional limitation associated with choloria or dark urine, 2 days before admission. He did not present muscular pains in other location and did not have history of using another medication. At physical examination, vital signs were normal, with edema and pain in the bilateral bicipital region associated to limitation for flexion-extension of shoulders and elbows. The admission laboratories reported hemoglobin (Hb) 16.1 mg/dL, leukocytes 9040 cells/mL with normal differential, platelets 243 000 cells/mL, creatinine (Cr) 1.01 mg/dL, serum nitrogen 25 mg/dL, CPK 85 380 mg/dL, lactic dehydrogenase (LDH) 2180 U/L, and aldolase 15.94 U/L. Similarly, laboratories were performed to rule out infectious or autoimmune etiology explaining the symptoms, which were negative. He was transferred to the intensive care unit (ICU) where he received fluid therapy because of the high risk of deterioration of renal function, very high CPK levels, and a history of obstructive uropathy. In this episode, magnetic resonance imaging (MRI) was not performed. During his stay in the ICU, there was no azotemia and his CPK level decreased to 5068 mg/dL with disappearance of myalgias. At discharge, alternate management for rosacea was recommended.

One year after this hospitalization, the cutaneous symptoms worsened and the patient voluntarily restarted isotretinoin, and 5 months later he presented with pain in the lower third of the right lower limb with slight limitation for walking. The physical examination revealed pain on the palpation of the posterior aspect of the right leg without other associated findings. The laboratory studies showed: Hb 14.5 mg/dL, leukocytes 5458 cells/mL, platelets 452 000 cells/mL, Cr 1.2 mg/dL (with 0.9 mg/dL prior) and CPK 152 mg/dL. MRI of the lower limbs was performed and showed changes in signal intensity in the muscular belly of the flexor digitorum longus, posterior tibialis, gastrocnemius, and to a lesser extent the extensor digitorum, compatible with multifocal myositis (see Figure 1). The medication with clinical improvement was suspended after 2 weeks of follow-up.

Discussion

We present here the case of a patient with recurrent myositis secondary to isotretinoin use with 2 episodes in different muscle groups with marked increase in CPK (first event) and alteration in MRI (second event) with complete recovery after agent suspension. Drug-induced myopathy is among the most common causes of muscle disease and includes alcohol, glucocorticoids, statins, cocaine, antimalarial drugs, antipsychotic drugs, colchicine, zidovudine, interferon, tumor necrosis factor-α inhibitors, and chemotherapeutic agents (e.g., gemcitabine) [6]. Other drugs with muscle involvement include vitamin A derivatives such our case and has a broad spectrum of manifestations [2].

First-generation retinoids, such as isotretinoin and all-trans retinoic acid (ATRA), are the most commonly used agents for the treatment of acne and acute promyelocytic leukemia (APL). Musculoskeletal adverse events are the most frequent, occurring from 16% to 51% of patients receiving this therapy [7,8]. These manifestations usually appear in the first month of treatment [9], usually associated with intense physical activity. The spectrum of clinical scenarios includes self-limited myalgias, asymptomatic and transient elevation of CPK to severe forms...
of inflammatory myopathies like malignant rhabdomyolysis and necrotizing myositis that in some cases can be fatal [10].

The forms of myositis associated with ATRA in patients with APL present with fever, pleural and pericardial effusion, renal function compromise, increased acute phase reactants and life-threatening complications, establishing the differentiation syndrome [11].

Focal myositis is one of the forms of muscular compromise associated with retinoids. This is defined by pseudo-tumoral inflammation of a muscle. The multifocal commitment given by the commitment of several muscle groups has also been described with the use of vitamin A analogues [12,13]. Differential diagnoses include denervation lesions secondary to radiculopathy, mechanical (trauma or intramuscular malformation), infectious diseases by virus (influenza, Coxsackie virus, cytomegalovirus), bacteria (Lyme disease, Mycobacterium tuberculosis), fungi (Candida, Aspergillus), or parasites (Toxoplasma gondii, Trypanosoma cruzi, Sarcocystis, Taenia solium, Trichinella); autoimmune diseases (systemic lupus erythematosus, Sjögren’s syndrome), autoinflammatory (Behçet’s disease), and other medications like statins or idiopathic causes [14]. In this reported case there was a clear temporal relationship between the onset of symptoms and the consumption of isotretinoin in both episodes (increase in CPK and multifocal myositis). Infectious, autoimmune and other causal medications were ruled out.

The laboratory studies should include CPK, which have been shown to be elevated in 37% to 41% of the reported case series [7,15]. The acute phase reactants might be normal. Electrodiagnostic studies are a tool to differentiate focal versus multifocal muscle involvement, as well to determine peripheral nerve injury [14]. MRI is one of the key diagnostic tools. Hyperintensity in T2 and hypointensity in T1 are often identified in affected muscle with respect to normal muscles, accompanied by edema of surrounding tissues [16]. Muscle biopsy is performed in cases where there is doubt in the diagnosis.

The muscle compromise associated with retinoids usually has a benign course and yield with the administration of analgesics and suspension of medication. In some cases, myalgias may persist for several months [17].

The diagnosis of myositis associated with retinoids in our patient was justified for the following reasons: 1) temporal relationship in both episodes with the ingestion of the medication; 2) para-clinics ruled out infectious or metabolic causes; 3) findings on MRI during the second episode are compatible with multifocal myositis; and 4) improvement of the symptoms after the suspension of the therapy and the reappearance with the reintroduction of the same. The patient did not have weakness only pain and it was evident in the first episode for the diagnosis of rhabdomyolysis, on the other hand, in the second episode the symptoms were oriented to focal myositis, with no evidence of multifocal or nerve involvement. For this reason, in the case of our patient, no electrodiagnostic studies or muscle biopsy were performed. Finally, although the imaging findings of inflammation observed in focal myositis

![Figure 1](image-url)

**Figure 1.** Magnetic resonance imaging of lower limbs. (A) Coronal section in T1 fat saturation with increased signal intensity in extensor digitorum longus and tibialis posterior with fat cross-linking in the posteromedial region of the distal third of the leg and ankle (B). Axial section in T2 with fat saturation in the lower third of the right leg. Hyperintensity is observed in the flexor and extensor compartment of the leg.
Table 1. Cases of myopathy associated with retinoids reported in the literature (PubMed, Scopus, Embase).

| Study                       | Diagnosis                  | Sex | Age | Location         | Medication          | Time (days) | CPK | EMG | MRI | BX | Death |
|-----------------------------|----------------------------|-----|-----|------------------|---------------------|--------------|-----|-----|-----|----|-------|
| Sameem et al. (2016) [13]   | Folliculitis decalvans     | M   | 25  | Pelvic           | Isotretinoin        | 30           | Elevated | Yes | No | No | No   |
| Miranda et al. (1994) [5]   | APL                        | M   | 33  | Lower members    | Tretinoin 45 mg/m²  | 18           | Elevated | No  | No | Yes | No   |
| Mangodt et al. (2018) [18]  | Acne                       | M   | 15  | Shoulders        | Isotretinoin 20 mg (44 kg) | 42 | Not reported | No  | No | No | No   |
| Hartung et al. (2012) [10]  | Acne conglobate            | M   | 20  | Generalized      | Isotretinoin 40 mg/day | 10           | High   | No  | No | Yes | Yes  |
| Alam et al. (2016) [19]     | Acne vulgaris              | M   | 31  | Extraocular muscles | Isotretinoin 1 mg/kg per day | 60 | Not reported | No  | Yes | No | No   |
| Yu et al. (2009) [9]        | LPA                        | F   | 51  | Buttocks         | ATRA 45 mg/m²       | 18           | Normal  | Yes | Yes | No | No   |
| Fiallo et al. (1996) [4]    | Acne                       | F   | 19  | Generalized      | Isotretinoin 0.5 mg/kg | 90           | Normal  | Yes | No | Yes | No   |
| Fiallo et al. (1996) [4]    | Nodulocytic acne           | M   | 20  | Generalized      | Isotretinoin 0.5 mg/kg | 15           | Normal  | No  | No | No | No   |
| Lister et al. (1996) [3]    | Erythrodermic psoriasis    | M   | 64  | Generalized      | Acitretin 50 mg per day | 14           | High    | Yes | No | Yes | No   |
| Ghelli et al. (2017) [20]   | LPA                        | M   | 43  | Generalized      | ATRA 45 mg/m²       | 44           | High    | No  | Yes | Yes | No   |
| Pecker et al. (2014) [16]   | LPA                        | M   | 15  | Thigh            | ATRA 45 mg/m²       | 30           | Elevated | No  | Yes | No | No   |
| Mangiani et al. (2009) [21] | LPA                        | F   | 5   | Calf             | ATRA 45 mg/m²       | 10           | High    | No  | Yes | No | No   |
| Oliveira et al. (2008) [22] | LPA                        | F   | 29  | Calf             | ATRA 45 mg/m²       | 21           | Normal  | No  | Yes | No | No   |
| Kanna et al. (2005) [23]    | LPA                        | F   | 18  | Thigh            | ATRA 45 mg/m²       | 5           | Not reported | No  | Yes | No | No   |
| Martinez-Chamorro et al. (2002) [24] | LPA                  | F   | 28  | Calf             | ATRA 45 mg/m²       | 6           | Normal  | Yes | Yes | No | No   |
| Fabbiano et al. (2005) [25] | LPA                        | M   | 45  | Lower limbs and myocardium | ATRA 45 mg/m²       | 23           | High    | No  | No | No | No   |
| Van Der Vliet et al. (2000) [26] | APL                  | M   | 39  | Legs and thighs  | ATRA 45 mg/m²       | 18           | Normal  | No  | Yes | No | No   |
| Van Der Vliet et al. (2000) [26] | LPA                  | F   | 35  | Legs previous    | ATRA 45 mg/m²       | 20           | Elevated | No  | Yes | No | No   |
| Chan et al. (2005) [27]     | LPA                        | M   | 27  | Calves           | ATRA 45 mg/m²       | 16           | Elevated | No  | Yes | No | No   |
| Citak et al. (2006) [28]    | LPA                        | F   | 11  | Legs and arms    | ATRA 45 mg/m² per day | 5           | Normal  | No  | Yes | No | No   |
| Corpuz et al. (2014) [29]   | LPA                        | M   | 24  | Thighs           | ATRA 45 mg/m²       | 3           | High    | No  | No | No | No   |
| Tae-Young et al. (2013) [30] | LPA                        | M   | 64  | Calves           | ATRA 45 mg/m²       | 17           | High    | No  | Yes | Yes | Yes  |
can mimic that of muscular dystrophy or inflammatory myopathy, the clinical evolution of our patient ruled out these diagnoses. The other hand, the patient did not present with weakness and remained a focal process.

We searched for reported cases of myositis related to retinoids. We found 23 articles with 25 patients (see Table 1). The majority of patients were male younger than 35 years of age, with symptom onset time within 30 days after initiating the medication and symptoms affecting the lower limbs.

Drug-induced myopathies require great attention because they cause great morbidity and in some cases are fatal. The timely suspension of medication prevents the progression of symptoms and related complications. This justifies the early identification of the clinical picture and its possible causative agents.

References:

1. Melnik B: Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol, 2017; 97: 173–81
2. Ginsberg H, Rubenstein A, Brown WV: Medical complications of isotretinoin. Clin Dermatol, 1986; 4: 183–89
3. Lister RK, Lecky BR, Lewis-Jones MS, Young CA: Acitretin-induced myopathy. Br J Dermatol, 1996; 134: 989–90
4. Fiallo P, Tagliapietra AG: Severe acute myopathy induced by isotretinoin. Arch Dermatol, 1996; 132: 1521–22
5. Miranda N, Oliveira P, Frade MJ et al: Myositis with tretinoin. Lancet, 1994; 344: 1096
6. Vallyll R, Christopher-Stine L: Drug-related myopathies of the which the clinician should be aware. Curr Rheumatol Rep, 2010; 12: 213–20
7. Heudes AM, Laroche L: [Muscular damage during isotretinoin treatment]. Ann Dermatol Venereol, 1998; 125: 94–97 [in French]
8. Dicken CH: Retinoids: A review. J Am Acad Dermatol, 1984; 11: 541–52
9. Yu W, Burns CM: All-trans retinoic acid-induced focal myositis, synovitis, and mononeuropathy. J Clin Rheumatol, 2009; 15: 358–60
10. Hartung B, Merk HF, Huckenbeck W et al: Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. Int J Legal Med, 2012; 126: 953–56
11. Montesinos P, Sanz MA: The differentiation syndrome in patients with acute promyelocytic leukemia: Experience of the PETHEMA group and review of the literature. Medit J Hematol Infect Dis, 2011; 3: e2011059
12. Janati A, AlGhasab NS, Ghorbel S et al: Pelvic girdle myopathy caused by isotretinoin: Case report and discussion of pathophysiology. J Clin Exp Pathol, 2014; 42: 160
13. Semira SF: Isotretinoin-induced acute severe myopathy involving pelvic girdle muscles: A case report. Indian J Pharmacol, 2016; 48: 601–3
14. Devic P, Gallay L, Streichenberger N, Petiot P: Focal myositis: A review. Neuromuscul Disord, 2016; 26: 725–33
15. Landau M, Mesterman R, Ophir J et al: Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol, 2001; 81: 350–52
16. Pecker LH, Tsai J, Angiolillo A: All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia. Pediatr Radiol, 2014; 44: 1039–41
17. Bigby M, Stern RS: Adverse reactions to isotretinoin. J Am Acad Dermatol, 1988; 18: 543–52
18. Mangoldt TC, Joos R, Siozopoulou V et al: Perinuclear antineutrophil cytoplasmic antibody-positive vasculitis, oligoarthritis, tendinitis, and myositis associated with isotretinoin in a 15-year-old boy. Case report and review of literature. Pediatr Dermatol, 2018; 35: e173–77

Table 1 continued. Cases of myopathy associated with retinoids reported in the literature (PubMed, Scopus, Embase).

| Study | Diagnosis | Sex | Age | Location | Medication | Time (days) | CPK | EMG | MRI | BX | Death |
|-------|-----------|-----|-----|----------|------------|-------------|------|-----|-----|----|-------|
| Khan et al. (2012) [12] | Acne vulgaris | M | 14 | Buttocks and adductors of the thighs, quadriceps bilateral femoral | Isotretinoin | 30 days | Normal | Yes | No | Yes | No |
| Mayorga-Bajo et al. (2016) [31] | LPA | M | 47 | Lower member | ATRA 45 mg/m² per day | 24 | Normal | No | Yes | Yes | No |
| Sarifakiouglu et al. (2011) [32] | Acne nodulocystic | M | 15 | Drumsticks | Isotretinoin 0.5 mg/kg per day | 14 days | Normal | Yes | No | Yes | No |

LPA – acute promyelocytic leukemia; Bx – muscle biopsy; MRI – magnetic resonance imaging; EMG – electromyography; CPK – creatine phosphokinase; M – Male; F – Female.

Conclusions

Drug-induced myositis should be taken into consideration in the differential diagnosis of myopathic syndromes. Retinoids have the potential to cause varying degrees of myositis and their rapid identification could prevent major complications.

Conflicts of interest

None.
19. Alam MS, Agarwal S: Presumed isotretinoin-induced extraocular myop-athy. J Pharmacol Pharmacother, 2016; 7: 187
20. Ghelfi A, Vismara V, Buffoni M et al: Miositis inducida por ácido trans-retinoico. Hematología, 2017; 21: 207–11 [in Spanish]
21. Manglani MV, Balamurugan P: All trans retinoic acid (ATRA) induced myositis. Indian Pediatr, 2009; 46: 912–13
22. Oliveira AC, Domingo-Domenech E, Arnan M et al: All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia. Int J Lab Hematol, 2008; 30: 254–55
23. Kannan K, Khan H, Jain R et al: All-trans retinoic acid-induced myositis. Br J Haematol, 2005; 131: 560
24. Martínez-Chamorro C, Martínez E, Gil-Fernández JI et al: ATRA-induced myositis in induction therapy of acute promyelocytic leukemia. Haematologica, 2002; 87: ECR08
25. Fabbiani F, Magrin S, Cangialosi C et al: All-trans retinoic acid induced cardiac and skeletal myositis in induction therapy of acute promyelocytic leukaemia. Br J Haematol, 2005; 129: 444–45
26. van Der Vliet HI, Roberson AE, Hogan MC et al: All-trans-retinoic acid-induced myositis: A description of two patients. Am J Hematol, 2000; 63: 94–98
27. Chan KH, Yuen SLS, Joshua D: A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. Clin Lab Haematol, 2005; 27: 399–401
28. Citak FE, Ezer U, Akkaya E et al: All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukaemia. Haematologica, 2006; 91: ECR35
29. Corpuz A, Manapat-Reyes B: All-trans retinoic acid-induced myositis and synovitis. Int J Rheum Dis, 2014; 17: 98
30. Kim T-Y, Maeng CH, Kim S-Y et al: All-trans retinoic acid-induced myositis and retinoic acid syndrome in microgranular-variant acute promyelocytic leukemia. Lab Med, 2013; 44: 348–52
31. Mayorga-Bajo I, Ortega-Valín L, Fuertes M, Ramos F: All-trans retinoic acid-induced myositis during treatment of acute promyelocytic leukemia. Case Reports Intern Med, 2016; 3: 46–49
32. Sarıfakıoğlu E, Onur O, Kart H, Yılmaz AE: Acute myopathy and acne fulmi-nans triggered by isotretinoin therapy. Eur J Dermatol, 2011; 21: 794–95